AASLD The Liver Meeting Boston MA November 2016 Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed Sunday, November ... National AIDS Treatment Advocacy Project, 2 weeks ago
Merck & Co. Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection - BioSpace, 2 weeks ago
Merck : Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection - 4 Traders, 2 weeks ago
Pune, India -- (SBWIRE) -- 11/02/2016 -- Hepatitis C (hep C) is a viral disease caused by the Hepatitis C virus (HCV) and transmitted by blood, primarily in health care settings. It can progressively damage the liver, and, if left untreated, cause ...Digital Journal, 4 weeks ago
European Center for Disease Prevention and Control: 2013 HIV/AIDS surveillance in Europe- WHO Regional Office for Europe. Copenhagen 27 Nov 2014. Platt L, Jolley E, Hope V, et al. HIV in the European Region: Using Evidence to Strengthen Policy ...General Medicine eJournal, 1 month ago
Introduction Recent advances in the field of tumor immunology, such as the discovery of monoclonal antibodies targeting immune checkpoints, have opened a new frontier in the fight against cancer. These monoclonal antibodies recognize and inhibit ...Frontiers in Neurorobotics, 1 month ago
on your WebpageAdd Widget >Get your members hooked!